On the landscape of China’s medical device industry in 2026, medical endoscopy stands out as the most remarkable growth driver. For single‑use endoscopes in particular, the global market expanded from USD 700 million in 2020 to USD 2.5 billion in 2024, and is projected to exceed USD 6.4 billion by 2030. It boasts a 10‑year compound annual growth rate (CAGR) of 24.77%, far outpacing the 7.64% growth of the overall endoscopy market.
Amid this industrial wave, Chinese domestic enterprises are no longer mere bystanders. Through continuous technological breakthroughs, comprehensive product portfolios and global market expansion, they have achieved explosive shipment growth, fundamentally breaking the long‑standing market monopoly held by overseas brands. Driven by continuously upgraded domestic healthcare‑associated infection control standards, the expanding tiered‑medical‑care system, and surging global demand for minimally‑invasive procedures, the domestic endoscopy industry is presented with unprecedented development opportunities.
Domestic endoscopes are rapidly penetrating diverse clinical scenarios, spanning urology, pulmonology, gastroenterology and hepatobiliary specialties, from grassroots township hospitals to top‑tier Grade‑A hospitals. A cohort of local manufacturers, including SonoScape, Xishan Technology, Shenda Endoscope, Viestar, HugeMed and Healnoc, are composing a new chapter for the localization of China’s high-end medical devices with robust technical capabilities and large‑volume shipment figures.
Meanwhile, overseas expansion of domestic products keeps accelerating. Leveraging outstanding cost‑performance and responsive localized services, these products have gained fast‑growing market share across Europe, the Americas, Southeast Asia and beyond. China’s single‑use endoscope industry has formally transitioned from the phase of “domestic substitution” into a new era of “global‑scale competition”.
In the tide of industrial development, it is not statistics themselves that define an era, but enterprises that turn figures into reality through products and technologies. The transformation of domestic endoscopes — from “being manufacturable” to “performing well”, and from “being usable” to “being the preferred choice” — is being advanced by local companies with persistent R&D focus, deep clinical insights and global vision.
Held in Nanjing on July 22‑23, 2026, this event emerges in response to industry trends.
The event brings together a host of outstanding enterprises including SonoScape, Xishan Technology, Shenda Endoscope, Viestar, HugeMed, Healnoc, shinevia, LINECOM and HappinessWorks. They will showcase their flagship innovative products and solutions at CCME 2026 Endoscopy Conference.
The participation of these leading enterprises validates CCME Endoscopy Conference as a key industry barometer. More than an exhibition platform, it serves as a pivotal milestone for domestic endoscopy players advancing from “domestic substitution” toward “global competition”.
You are cordially invited to join these industry leaders, witness the robust strengths of Chinese‑made endoscopes, and tap into boundless opportunities across the global market.
Sonoscape Medical Corp
Sonoscape Medical Corp. is a domestic leader in China’s gastroenterological endoscopy sector. For 24 years, it has devoted itself to independent innovation of high-end medical imaging equipment, building four complete business portfolios covering ultrasound, flexible endoscopy, minimally-invasive rigid endoscopy, and cardiovascular interventional devices.
Sonoscape delivered an outstanding financial performance in 2025: full-year operating revenue reached RMB 2.3 billion, up 15% year-on-year. The endoscopy segment generated annual revenue of RMB 1.014 billion, a 27.42% increase. Sonoscape ranks No. 1 among domestic gastroenterological endoscopy brands.
Zhejiang Healnoc Technology Co., Ltd.
Built on the video-technology heritage of Dahua Technology, Healnoc specializes in the R&D and manufacturing of medical endoscopic imaging systems. masters a complete set of underlying technologies ranging from CMOS imaging, ISP image processing, fluorescence fusion and AI intelligent enhancement.
- Surgical rigid endoscope systems: 4K white-light / fluorescence.
- Endoscope supporting equipment: LED cold light sources, insufflators.
- Disposable minimally-invasive endoscopes: Flexible ureteroscopes.
- Digital supporting solutions: AI intra-operative evaluation systems.
Chongqing Xishan Technology Co., Ltd.
A leading enterprise in China’s surgical device sector, focusing on three major segments: Surgical Power Instruments, Endoscope Systems, and Energy-based Surgical Devices.
Speaker: Wang Xiongwei / R&D Director
Topic: From Objective Lens to System — Xishan Technology’s Full chain Independent R&D Breakthroughs in Endoscopy
Booth No.: D016
Lepu Medical Shenyang Shenda Endoscope Co., Ltd.
As a pioneer and market leader in China’s medical rigid endoscope industry, Shenda Endoscope has filled multiple domestic technological gaps and ranks first in market share among domestic rigid-endoscope brands.
Speaker: Gao Yuxi / Marketing Director, Lepu General Surgery Business Unit
Topic: From Cardiology to Minimally-Invasive Surgery — Synergistic Development of the Industry
Booth No.: D030
Viestar Medical Technology (Wuhan) Co., Ltd.
Viestar Medical is the world’s second and China’s first enterprise that has successfully developed confocal micro endoscopes. In 2026, the self developed BIOPSEE® confocal micro endoscope was selected into the 11th Catalogue of Excellent Domestic Medical Devices.
Speaker: Ding Mang / R&D Director
Topic: Confocal Micro endoscope: Ushering in a New Era of “Optical Biopsy”
Booth No.: E006
Shenzhen HugeMed Medical Technology Development Co., Ltd.
A top-tier enterprise in the single-use endoscope industry, holding more than 110 core patents. HugeMed launched the world’s first single-use digital flexible ureteroscope with 6.3 Fr outer diameter, setting a new global technical benchmark.
HugeMed’s single-use endoscopes are available in over 1,000 hospitals across 43 European countries.
KARL STORZ SE & Co. KG
Founded in 1945 in Germany, KARL STORZ is the inventor of the endoscope and the global leader in rigid endoscopy. In 2024, KARL STORZ opened its first Asia-Pacific production base in Songjiang, Shanghai, realizing the strategy of “Manufacturing in China for the Chinese market”.
Anhui HappinessWorks Medical Equipment Co., Ltd.
Focuses on single-use ultra-thin electronic endoscopes. In 2026, its single-use digital flexible ureteroscope (7.5F) obtained US FDA 510(k) clearance.
Speaker: Han Tiegong / Chairman
Topic: Single – use Endoscopes: From Made‑in‑China to Global Standards
Booth No.: E006
The rise of domestic endoscopes is only half the story—every procedure relies on precision disposable accessories. ZRHmed (Jiangxi Zhuoruihua Medical), specializing in endoscopic consumables since 2018, offers a full portfolio:
With MDR CE certification and ISO 13485 accreditation, ZRHmed products are exported to over 30 countries. As manufacturers expand globally, ZRHmed stands as a reliable, full process accessory partner.
The rise of China’s domestic endoscope industry — from technological follower to partial frontrunner, and from domestic import‑substitution to global layout — serves as a microcosm of the development of China’s high‑end medical device sector. The explosive growth of industry‑wide shipments in 2025 is an inevitable outcome of long‑term accumulation.
Going forward, with continuous iteration of core technologies, growing overseas regulatory clearances, and outstanding cost‑performance, Chinese endoscope manufacturers are bound to capture greater global market share. Clinical patients across more countries will gain access to inclusive medical services empowered by Chinese innovative technologies.
Guided by the Healthy China Initiative, the domestic endoscope industry is blazing an innovative path for the growth of China’s high‑end medical devices, contributing Chinese expertise to the global cause of minimally‑invasive diagnosis and treatment.
Post time: Sep-08-2026